Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 1
2012 2
2013 1
2014 2
2015 3
2016 13
2017 6
2018 7
2019 11
2020 12
2021 5
2022 10
2023 3
2024 8
2025 9
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Recent advances in the treatment of irritable bowel syndrome.
Bonetto S, Fagoonee S, Battaglia E, Grassini M, Saracco GM, Pellicano R. Bonetto S, et al. Pol Arch Intern Med. 2021 Aug 30;131(7-8):709-715. doi: 10.20452/pamw.16067. Epub 2021 Aug 30. Pol Arch Intern Med. 2021. PMID: 34463082 Free article. Review.
Four different entities of IBS have been identified: IBS with constipation (IBS- C), IBS with diarrhea (IBS D), IBS with a mixed pattern of constipation and diarrhea, and unclassified IBS. ...The choice of pharmacological treatment is based on the predominant …
Four different entities of IBS have been identified: IBS with constipation (IBS- C), IBS with diarrhea (IBS D), IBS wit …
Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D.
Singh P, Alm EJ, Kelley JM, Cheng V, Smith M, Kassam Z, Nee J, Iturrino J, Lembo A. Singh P, et al. Gut Microbes. 2022 Jan-Dec;14(1):2020067. doi: 10.1080/19490976.2021.2020067. Gut Microbes. 2022. PMID: 35014601 Free PMC article. Clinical Trial.
Fecal microbiota transplantation (FMT) is an attractive strategy to correct microbial dysbiosis in diarrhea-predominant irritable bowel syndrome (IBS-D). Although the mechanism of FMT is thought to be bacterial engraftment, the best approach to achieve engraftment a …
Fecal microbiota transplantation (FMT) is an attractive strategy to correct microbial dysbiosis in diarrhea-predominant irritable bowel synd …
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.
Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Savarino E, et al. United European Gastroenterol J. 2022 Jul;10(6):556-584. doi: 10.1002/ueg2.12259. Epub 2022 Jun 13. United European Gastroenterol J. 2022. PMID: 35695704 Free PMC article. Review.
Irritable bowel syndrome with diarrhoea (IBS-D) and functional diarrhoea (FDr) are the two major functional bowel disorders characterized by diarrhoea. ...A multinational group of European experts summarized the current state of consensus on the definition, diagnosi …
Irritable bowel syndrome with diarrhoea (IBS-D) and functional diarrhoea (FDr) are the two major functional bowel disorders ch …
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. Lembo A, et al. Gastroenterology. 2022 Jul;163(1):137-151. doi: 10.1053/j.gastro.2022.04.017. Gastroenterology. 2022. PMID: 35738725
This American Gastroenterological Association Guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS with predominant diarrhea (IBS-D) and is an update of a prior technical review and guidel …
This American Gastroenterological Association Guideline is intended to support practitioners in decisions about the use of medications for t …
A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence.
Papale AJ, Flattau R, Vithlani N, Mahajan D, Nadella S. Papale AJ, et al. J Clin Med. 2024 Nov 18;13(22):6948. doi: 10.3390/jcm13226948. J Clin Med. 2024. PMID: 39598092 Free PMC article. Review.
IBS is classified into several subtypes based on predominant presenting symptoms, including IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D), with each requiring targeted approaches to treatment. Some treatments, such as psychotherapy, dietary interventio …
IBS is classified into several subtypes based on predominant presenting symptoms, including IBS with constipation (IBS-C) and IBS with diarr …
Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024.
Remes-Troche JM, Coss-Adame E, Schmulson M, García-Zermeño KR, Amieva-Balmori M, Carmona-Sánchez R, Gómez-Escudero O, Gómez-Castaños PC, Icaza-Chávez ME, López-Colombo A, Morel-Cerda EC, Valdovinos-Díaz MÁ, Valdovinos-García LR, Villar-Chávez AS. Remes-Troche JM, et al. Rev Gastroenterol Mex (Engl Ed). 2025 Jan-Mar;90(1):77-110. doi: 10.1016/j.rgmxen.2024.10.009. Epub 2025 Apr 29. Rev Gastroenterol Mex (Engl Ed). 2025. PMID: 40307155 Free article. Review.
Antispasmodics (alone or combined) are used as first-line therapy for pain management, whereas antidiarrheals, such as loperamide, are used for reducing diarrhea in diarrhea-predominant IBS (IBS-D) and laxatives are used for constipation in constipation-predominant …
Antispasmodics (alone or combined) are used as first-line therapy for pain management, whereas antidiarrheals, such as loperamide, are used …
Novel Therapies in IBS-D Treatment.
Nee J, Zakari M, Lembo AJ. Nee J, et al. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5. Curr Treat Options Gastroenterol. 2015. PMID: 26432092
There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Alosetron was initially approved by FDA 2000; however, its use is now limited to women with severe IBS-D symptoms refractory to …
There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Al …
Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).
Nee J, Lembo A. Nee J, et al. Aliment Pharmacol Ther. 2021 Dec;54 Suppl 1:S63-S74. doi: 10.1111/apt.16625. Aliment Pharmacol Ther. 2021. PMID: 34927757 Review.
AIM: The goal of this article was to provide an up-to-date review of the current evidence for both non-pharmacological and pharmacological treatment options in IBS-D and IBS-M. Future treatments for IBS-D and IBS-M will also be discussed. METHODS: Medl …
AIM: The goal of this article was to provide an up-to-date review of the current evidence for both non-pharmacological and pharmacological t …
Vitamin D Deficiency (VDD) and Benefits of Supplementation in Veterans with IBS-D.
Kesavan C, Das A, Goyal P, Jackson CS, Strong DD, Strong RM. Kesavan C, et al. Diagnostics (Basel). 2023 Aug 30;13(17):2807. doi: 10.3390/diagnostics13172807. Diagnostics (Basel). 2023. PMID: 37685345 Free PMC article.
All patients completed a workup that included serologies (IBD, celiac), routine laboratory tests (CBC, chemistry panels, TSH, T4, CRP), cultures for enteric pathogens (C diff, bacteria, viruses, small intestinal bacterial overgrowth (SIBO)), and upper and lower endoscopies with h …
All patients completed a workup that included serologies (IBD, celiac), routine laboratory tests (CBC, chemistry panels, TSH, T4, CRP), cult …
Inflammatory Prostatitis Plus IBS-D Subtype and Correlation with Immunomodulating Agent Imbalance in Seminal Plasma: Novel Combined Treatment.
Castiglione R, Bertino G, Vicari BO, Rizzotto A, Sidoti G, D'Agati P, Salemi M, Malaguarnera G, Vicari E. Castiglione R, et al. Diseases. 2024 Oct 18;12(10):260. doi: 10.3390/diseases12100260. Diseases. 2024. PMID: 39452503 Free PMC article.
We recently demonstrated the effectiveness of long-term treatment with rifaximin and the probiotic DSF (De Simone formulation) in improving urogenital and gastrointestinal symptoms in patients with both chronic inflammatory prostatitis (IIIa prostatitis) and diarrhea-predo …
We recently demonstrated the effectiveness of long-term treatment with rifaximin and the probiotic DSF (De Simone formulation) in imp …
91 results